CIC
SUPN icon

Chase Investment Counsel’s Supernus Pharmaceuticals SUPN Stock Holding History

Chase Investment Counsel’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,145
Closed -$444K – 97
2017
Q4 		$444K Sell
11,145
-450
-4% -$17.8K 0.23% 62
2017
Q3 		$463K Sell
11,595
-4,100
-26% -$177K 0.24% 62
2017
Q2 		$676K Buy
+15,695
New +$559K 0.33% 58

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Chase Investment Counsel's SUPN Position: Q1 2018 in Review

Chase Investment Counsel sold out of Supernus Pharmaceuticals (SUPN) in Q1 2018, closing a stake of 11,145 shares — an estimated $444K sold.

Chase Investment Counsel first reported a position in SUPN in Q2 2017 and held it in 3 quarters. The position peaked at $676K in Q2 2017. 312 funds tracked by Wall St. Rank hold SUPN as of Q1 2018.

  • Chase Investment Counsel reported no remaining Supernus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Chase Investment Counsel sold 11,145 Supernus Pharmaceuticals shares in Q1 2018, an estimated $444K.
  • Chase Investment Counsel first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Chase Investment Counsel's Supernus Pharmaceuticals position peaked at $676K in Q2 2017.
  • 312 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2018.

Based on Chase Investment Counsel's 13F filing for Q1 2018, filed 7 May 2018.